Aim: Timing of radium-223 (Ra-223) in metastatic castration-resistant prostate cancer (mCRPC) remains challenging due to alternative options and short window of opportunity. Methods: Ra-223 treated patients in the CAPRI-registry were included. Outcomes were evaluated based on treatment line of Ra-223. Results: Out of 285 patients, 49% received Ra-223 in line ≥3. 51% completed six Ra-223 injections and 34% had a symptomatic skeletal event after first Ra-223 without differences between subgroups. After correction of known prognostic factors Ra-223 in line ≥3 (HR: 3.267; 95% CI: 1.689-6.317; p < 0.01) remained associated with worse OS. Conclusion: In the Netherlands, Ra-223 was mainly started as second or third mCRPC-treatment in 2014-2018. Later timing of Ra-223 did affect OS, but not treatment completion and occurrence of symptomatic skeletal events.
|Number of pages||14|
|Publication status||Published - 29 May 2020|
Bibliographical noteFunding Information:
This research was funded by Sanofi-Aventis Netherlands BV., Janssen-Cilag BV, Astellas Pharma BV and Bayer BV. The funding organizations had no role in the design and conduct of the study, collection, management, analysis, interpretation of the data, and preparation, review or approval of the abstract.
MCP Kuppen has received travel/accommodation expenses from Ipsen; HM Westgeest has received travel/accommodation expenses from Ipsen, Sanofi and Celgene, and honoraria from Roche and Sanofi; MJ van der Doelen has received honoraria from Astellas, study grant from Bayer The Netherlands and and has a consulting/advisory role for Janssen-Cilag BV; AJM van den Eertwegh has received study grants from Sanofi and Roche, travel expenses from MSD Oncology, Roche, Pfizer and Sanofi, honoraria from Bristol-Myers Squibb, and is a member of the advisory board of Bristol-Myers Squibb, MSD Oncology, Amgen, Roche, Novartis, Sanofi, Pfizer, Ipsen and Merck; JLLM Coenen is a member of the advisory board of Sanofi; KKH Aben has no conflict of interest; ACM van den Bergh has no conflict of interest; AM Bergman has received study grants from Sanofi, Astellas and Bayer, travel/accommodation expenses from Sanofi, Astellas and Bayer, speakers fees of Sanofi, Astellas, Bayer and Janssen, and has an consulting/advisory role for Sanofi, Astellas and Bayer; J van den Bosch has no conflict of interest; F Celik has no conflict of interest; MP Hendriks has no conflict of interest; J Lavalaye has no conflict of interest; S van der Meer has received travel expenses from Astellas; MB Polee has no conflict of interest; DM Somford has received study grants from Astellas; IM van Oort has received study grants from Astellas, Janssen and Bayer, and has a consulting/advisory role for Astellas, Janssen, Bayer, Roche, Mdx health; CA Uyl-de Groot has received study grants from Boehringer Ingelheim, Astellas, Celgene, Sanofi, Janssen-Cilag, Bayer, Amgen, Genzyme, Merck, Glycostem Therapeutics, Astra Zeneca and Roche; W.R. Gerritsen has received speaker’s fees from Bayer and MSD, study grants from Bayer, Astellas and Janssen-Cilag, and is a member of the advisory board of Bristol-Myers Squibb, Astellas, Bayer, Sanofi, and Amgen. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed. No writing assistance was utilized in the production of this manuscript.